Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00176_DB00344_nanopub.RAQT-OU7En6yymUV21XRpIVIR6FdgCx5UbGK6n2xi4CQ8#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00176_DB00344 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00176_DB00344 label "DDI between Fluvoxamine and Protriptyline - The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, protriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of protriptyline if fluvoxamine is initiated, discontinued or dose changed. [drugbank_resource:DB00176_DB00344]" assertion.
- drugbank_resource:DB00176_DB00344 identifier "drugbank_resource:DB00176_DB00344" assertion.
- drugbank_resource:DB00176_DB00344 title "DDI between Fluvoxamine and Protriptyline - The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, protriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of protriptyline if fluvoxamine is initiated, discontinued or dose changed." assertion.
- drugbank:DB00176 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00176_DB00344 assertion.
- drugbank:DB00344 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00176_DB00344 assertion.